Rules/misleading presentation/US-MIS-024

Disclosing limitations does not cure a claim based on an inadequate study

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

If a promotional communication relies on a study that is inadequate to support the representation or suggestion made, disclosing the study's limitations does not cure the misleading message — the underlying claim itself must not overstate what the evidence supports.

Check

Check whether a limitations disclaimer is being used to accompany a claim that the underlying study cannot support at all. A violation looks like a strong claim followed by a limitations footnote, where the claim itself should not have been made.

Escalate when

Always — requires judgment on whether the core claim (not just the disclosure) is supportable.

Where this comes from

Q.6/A.6 · page 16. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…on the individual components need cautious interpretation and could represent chance findings. Thus, in addition to being scientifically appropriate and statistically sound, the evidence should be accurately characterized in the CFL promotional communication, including limitations of the strength of the evidence and the conclusions that can be drawn from it (as discussed in Q.8/A.8). However, firms should note that if a CFL promotional communication relies on a study that is inadequate to support the representations or suggestions it presents, disclosure of the material limitations of that study does not correct the misleading message conveyed by the communication. For example, in the scenario described in the previous paragraphs, if the firm’s communication represented or suggested that the results on the individual components are demonstrated additional effects of the drug, disclosing the limitations of the underlying evidence would not correct the misleading message conveyed by the communication. Rather, as previously mentioned, the information should be presented in a way…

Open the original at page 16 on fda.gov ↗Read our full copy →

Document: FDA guidance: Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: 1a18b7f242bfbbf897f198df…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is verbatim from the final paragraph of A.6 and is a direct statement of FDA's position ('firms should note that if a CFL promotional communication relies on a study that is inadequate to support the representations or suggestions it presents, disclosure of the material limitations of that study does not correct the misleading message'). The rule statement is a faithful restatement, including the corollary drawn straight from the next sentences of the source ('the information should be presented in a way that does not overstate the conclusions that can be drawn from the supporting evidence').
- Not overstated: the source itself says disclosure 'does not correct' the misleading message, and the rule says exactly that rather than escalating it into a prohibition with independent force.
- Atomic: a single checkable proposition — a limitations disclosure cannot rescue a claim the underlying study cannot support.
- 'judgment' is correct — it turns on whether the study is adequate to support the representation, which is an adequacy assessment, not presence/absence.
- 'guidance' is correct; severity 'warning' is defensible and consistent with the sibling overstatement rules from the same paragraph; locator Q.6/A.6 is right.
- Non-blocking observation (not grounds to withhold a pass): the rule statement says 'promotional communication' where the source says 'CFL promotional communication', and applies_when omits the basis: consistent-with-labeling limit that sibling rule US-SUB-008 carries. The principle is if anything stronger outside the CFL context, so the broadening does not make the rule wrong, but adding the limit would align the corpus.

Nearby rules

US-MIS-022 US-MIS-023 US-MIS-025 US-MIS-056 US-SUB-008